Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, this holiday season.
ICER performs studies that declare how much we as patients value medicines that treat devastating diseases like Alzheimer’s. And depending upon their proclamations, patients’ access to life-altering medicines can be meaningfully obstructed.
The organization has a long history of undervaluing medicines and recommending prices that don’t support innovation. Since 2017, ICER has declared three out of every four drugs overpriced based on data from the ICER Analytics platform.